132 related articles for article (PubMed ID: 3914816)
1. Gastric inhibitory polypeptide (GIP): a therapeutic possibility?
Moody AJ; Jones IR; Krarup T; Owens DR; Saurbrey N
Acta Paediatr Scand Suppl; 1985; 320():66-71. PubMed ID: 3914816
[No Abstract] [Full Text] [Related]
2. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
3. A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitus.
Jones IR; Owens DR; Vora J; Luzio SD; Hayes TM
Diabetes Res Clin Pract; 1989 Nov; 7(4):263-9. PubMed ID: 2693029
[TBL] [Abstract][Full Text] [Related]
4. Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus.
Krarup T; Saurbrey N; Moody AJ; Kühl C; Madsbad S
Metabolism; 1987 Jul; 36(7):677-82. PubMed ID: 3298936
[TBL] [Abstract][Full Text] [Related]
5. Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state.
Amland PF; Jorde R; Aanderud S; Burhol PG; Giercksky KE
Scand J Gastroenterol; 1985 Apr; 20(3):315-20. PubMed ID: 3890139
[TBL] [Abstract][Full Text] [Related]
6. Immunoreactive gastric inhibitory polypeptide response to a meal during the first eighteen months after diagnosis of type 1 (insulin dependent) diabetes mellitus.
Krarup T; Madsbad S; Moody AJ
J Clin Endocrinol Metab; 1985 Jan; 60(1):120-5. PubMed ID: 3880559
[TBL] [Abstract][Full Text] [Related]
7. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
8. Relation of immunoreactive gastric inhibitory polypeptide to changes in glycaemic control and B cell function in type 1 (insulin-dependent) diabetes mellitus.
Krarup T; Madsbad S; Regeur L; Faber OK; Tronier B
Acta Endocrinol (Copenh); 1984 Feb; 105(2):221-5. PubMed ID: 6364671
[TBL] [Abstract][Full Text] [Related]
9. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects.
Meier JJ; Nauck MA; Siepmann N; Greulich M; Holst JJ; Deacon CF; Schmidt WE; Gallwitz B
Metabolism; 2003 Dec; 52(12):1579-85. PubMed ID: 14669159
[TBL] [Abstract][Full Text] [Related]
10. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
[TBL] [Abstract][Full Text] [Related]
11. Gastric inhibitory polypeptide (GIP) response in diabetes using a highly specific antiserum.
Alam MJ; Kerr JI; Cormican K; Buchanan KD
Diabet Med; 1992 Jul; 9(6):542-5. PubMed ID: 1643802
[TBL] [Abstract][Full Text] [Related]
12. Cellular immune response to GAD in type 1 diabetes with residual beta-cell function.
Fukui M; Nakamura N; Nakano K; Kondo M
Diabetes Care; 1999 Oct; 22(10):1758-9. PubMed ID: 10526760
[No Abstract] [Full Text] [Related]
13. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests.
Mari A; Gastaldelli A; Natali A; Ostergard T; Schmitz O; Ferrannini E
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E541-6. PubMed ID: 15522997
[TBL] [Abstract][Full Text] [Related]
14. Synthetic gastric inhibitory polypeptide. Stimulatory effect on insulin and glucagon secretion in the rat.
Taminato T; Seino Y; Goto Y; Inoue Y; Kadowaki S
Diabetes; 1977 May; 26(5):480-4. PubMed ID: 323091
[TBL] [Abstract][Full Text] [Related]
15. The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide.
Meneilly GS; Bryer-Ash M; Elahi D
Diabetes Care; 1993 Jan; 16(1):110-4. PubMed ID: 8422763
[TBL] [Abstract][Full Text] [Related]
16. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes.
Christensen MB; Calanna S; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2014 Mar; 99(3):E418-26. PubMed ID: 24423311
[TBL] [Abstract][Full Text] [Related]
17. Interaction of fat-stimulated gastric inhibitory polypeptide on pancreatic alpha and beta cell function.
Verdonk CA; Rizza RA; Nelson RL; Go VL; Gerich JE; Service FJ
J Clin Invest; 1980 May; 65(5):1119-25. PubMed ID: 6988457
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of glucose profiles, insulin antibody levels and beta cells secretory patterns in non-obese Ugandan diabetic subjects.
Otim MA
East Afr Med J; 1988 Jan; 65(1):8-15. PubMed ID: 3046922
[No Abstract] [Full Text] [Related]
19. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.
Lynn FC; Pamir N; Ng EH; McIntosh CH; Kieffer TJ; Pederson RA
Diabetes; 2001 May; 50(5):1004-11. PubMed ID: 11334402
[TBL] [Abstract][Full Text] [Related]
20. Endocrine pancreatic response of children with onset of insulin-requiring diabetes before age 3 and after age 5.
Ternand C; Go VL; Gerich JE; Haymond MW
J Pediatr; 1982 Jul; 101(1):36-9. PubMed ID: 7045315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
